Stacha F. I. Reumers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stacha F. I. Reumers has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Nicol Cornelia Voermans
Department of Neurology, Donders Institute for Brain, Cognition and Behaviour Radboud University Medical Center Nijmegen The Netherlands
3 shared publications Corrie E. Erasmus
2 shared publicationsDennis J.L.G. Schutter
Department of Experimental Psychology Helmholtz Institute, Utrecht University Utrecht the Netherlands
2 shared publications- Frederik Braun
Institute of Human Genetics, University Hospital Essen, University Duisburg-Essen, Essen, Germany
2 shared publications Heinz Jungbluth
2 shared publicationsKarlijn Bouman
2 shared publications
Latest Publications
- Open Access
- 6 March 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (3) , 1-12
Cognition in cerebellar disorders: What’s in the profile? A systematic review and meta-analysis
Objective: This systematic review and meta-analysis aim to examine the profile and extent of cognitive deficits in patients with cerebellar disorders, and to provide a complete overview of the cognitive domains that might be affected in the Cerebellar Cognitive Affective Syndrome (CCAS). Methods: MEDLINE, Embase, PsycINFO, and Web of Science were systematically searched to 17-07-2024. Studies were considered if the participants were adult patients with a clinical diagnosis of cerebellar disorder and were neuropsychological assessed. Outcomes were grouped into the domains of processing speed, language, social cognition, executive function, visuospatial skills, episodic memory, verbal intelligence, attention, and working memory. All aetiologies were included for first evaluation and patients were assigned to one of two groups (focal vs. degenerative) for secondary evaluation. Random-effects models were employed for the meta-analyses. Results: 129 studies with a total of 3140 patients with cerebellar disorders were included. Patients performed significantly worse compared to control/standardized data in all domains. Deficits were most pronounced in processing speed, ES [95% CI] = − 0.83 [− 1.04, − 0.63], language, ES [95% CI] = − 0.81 [− 0.94, − 0.67], and social cognition, ES [95% CI] = − 0.81 [− 1.19, − 0.42]. Cognitive impairment varied between patients with focal cerebellar lesions and degenerative cerebellar disorders, but was overall worse in the degenerative group. Discussion: Cerebellar disorders can impact many cognitive domains, extending beyond executive functioning, visuospatial skills, and language. These outcomes contribute to a broader understanding of the cerebellum's role in cognition and sheds light on the cognitive deficits associated with cerebellar disorders.
- 6 March 2025
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (3) , 1-12
Open AccessCognition in cerebellar disorders: What’s in the profile? A systematic review and meta-analysis
Objective: This systematic review and meta-analysis aim to examine the profile and extent of cognitive deficits in patients with cerebellar disorders, and to provide a complete overview of the cognitive domains that might be affected in the Cerebellar Cognitive Affective Syndrome (CCAS). Methods: MEDLINE, Embase, PsycINFO, and Web of Science were systematically searched to 17-07-2024. Studies were considered if the participants were adult patients with a clinical diagnosis of cerebellar disorder and were neuropsychological assessed. Outcomes were grouped into the domains of processing speed, language, social cognition, executive function, visuospatial skills, episodic memory, verbal intelligence, attention, and working memory. All aetiologies were included for first evaluation and patients were assigned to one of two groups (focal vs. degenerative) for secondary evaluation. Random-effects models were employed for the meta-analyses. Results: 129 studies with a total of 3140 patients with cerebellar disorders were included. Patients performed significantly worse compared to control/standardized data in all domains. Deficits were most pronounced in processing speed, ES [95% CI] = − 0.83 [− 1.04, − 0.63], language, ES [95% CI] = − 0.81 [− 0.94, − 0.67], and social cognition, ES [95% CI] = − 0.81 [− 1.19, − 0.42]. Cognitive impairment varied between patients with focal cerebellar lesions and degenerative cerebellar disorders, but was overall worse in the degenerative group. Discussion: Cerebellar disorders can impact many cognitive domains, extending beyond executive functioning, visuospatial skills, and language. These outcomes contribute to a broader understanding of the cerebellum's role in cognition and sheds light on the cognitive deficits associated with cerebellar disorders.
- Open Access
- 2 November 2024
- Published by Wiley in Movement Disorders
- Vol. 40 (1) , 121-131
Cerebellar Transcranial Direct Current Stimulation in the Cerebellar Cognitive Affective Syndrome: A Randomized, Double‐Blind, Sham‐Controlled Trial
Background: The cerebellar cognitive affective syndrome (CCAS) encompasses cognitive and affective symptoms in patients with cerebellar disorders, for which no proven treatment is available.Objectives: Our primary objective was to study the effect of cerebellar anodal transcranial direct current stimulation (tDCS) on cognitive performance in CCAS patients. Secondary effects on ataxia severity, mood, and quality of life were explored.Methods: We performed a randomized, double‐blind, sham‐controlled trial. Thirty‐five patients with CCAS were included and received 10 sessions of 20 minutes sham (n = 17) or real (n = 18) tDCS, with a current of 2 mA. Cognitive performance was assessed using executive function subtests of the computerized Test of Attentional Performance (TAP), with the composite as primary endpoint. Secondary outcomes were ataxia severity, mood, and quality of life. Outcomes were evaluated 1, 3, 6, and 12 months post‐intervention.Results: Cerebellar tDCS was well tolerated and no serious adverse events related to the intervention occurred. No significant tDCS effect was found on cognitive performance. Improvement on the TAP was observed in the sham group 1 month post‐treatment (estimate = −0.248, 95% CI, −0.49 to −0.01), but not clinically relevant. A positive tDCS effect was observed for ataxia severity 1 month post‐treatment (estimate = −0.985, 95% CI, −1.94 to −0.03).Conclusions: Ten sessions of 20 minutes cerebellar anodal tDCS did not prove efficacious for CCAS‐related cognitive impairment, but a significant positive effect of tDCS was found for ataxia severity, aligning with previous findings indicative of tDCS as a therapeutic neuromodulation tool in cerebellar disorders. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- 2 November 2024
- Published by Wiley in Movement Disorders
- Vol. 40 (1) , 121-131
Open AccessCerebellar Transcranial Direct Current Stimulation in the Cerebellar Cognitive Affective Syndrome: A Randomized, Double‐Blind, Sham‐Controlled Trial
Background: The cerebellar cognitive affective syndrome (CCAS) encompasses cognitive and affective symptoms in patients with cerebellar disorders, for which no proven treatment is available.Objectives: Our primary objective was to study the effect of cerebellar anodal transcranial direct current stimulation (tDCS) on cognitive performance in CCAS patients. Secondary effects on ataxia severity, mood, and quality of life were explored.Methods: We performed a randomized, double‐blind, sham‐controlled trial. Thirty‐five patients with CCAS were included and received 10 sessions of 20 minutes sham (n = 17) or real (n = 18) tDCS, with a current of 2 mA. Cognitive performance was assessed using executive function subtests of the computerized Test of Attentional Performance (TAP), with the composite as primary endpoint. Secondary outcomes were ataxia severity, mood, and quality of life. Outcomes were evaluated 1, 3, 6, and 12 months post‐intervention.Results: Cerebellar tDCS was well tolerated and no serious adverse events related to the intervention occurred. No significant tDCS effect was found on cognitive performance. Improvement on the TAP was observed in the sham group 1 month post‐treatment (estimate = −0.248, 95% CI, −0.49 to −0.01), but not clinically relevant. A positive tDCS effect was observed for ataxia severity 1 month post‐treatment (estimate = −0.985, 95% CI, −1.94 to −0.03).Conclusions: Ten sessions of 20 minutes cerebellar anodal tDCS did not prove efficacious for CCAS‐related cognitive impairment, but a significant positive effect of tDCS was found for ataxia severity, aligning with previous findings indicative of tDCS as a therapeutic neuromodulation tool in cerebellar disorders. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
- Open Access
Cognitive impairment in young adults following cerebellar stroke: Prevalence and longitudinal course
- 15 November 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (20) , E2223-E2233
Neuromuscular Features in XL-MTM Carriers
Background X-linked myotubular myopathy (XL-MTM) is an early onset congenital myopathy characterized by mild to severe muscle weakness in males. Objective To characterize the clinical spectrum of neuromuscular features in X-linked myotubular myopathy (XL-MTM) carriers. Methods We performed a nationwide cross-sectional study focusing on neuromuscular features in an unselected cohort of Dutch XL-MTM carriers. Participants were recruited from neuromuscular centres in the Netherlands and through the Dutch and European patient associations. Genetic results were collected. Carriers were classified based on ambulatory status and muscle weakness. We used a questionnaire focussing on medical and family history and neuromuscular symptoms. Additionally, we performed a neurological examination including Manual Muscle Testing (MMT), Timed Up and Go test (TUG), and 6 Minutes Walking Test (6MWT). Results We included 21 carriers (20 genetically confirmed and one obligate), of whom eleven (52%) carriers were classified as manifesting, with severe (non-ambulatory; n=2), moderate (minimal independent ambulation/assisted ambulation; n=2), mild (independent ambulation but with limb or axial muscle weakness; n=3) and minimal (only facial muscle weakness, n=4) phenotypes. Three of the manifesting carriers (two severe, one moderate) were from families without genetically confirmed male XL-MTM patients. Furthermore, seven manifesting carriers (one moderate; two mild; four minimal) were not classified as manifesting carriers before participation in our study. Three carriers reported a history of pneumothorax. The obstetric history revealed frequent polyhydramnios (50%) and reduced fetal movements (36%) in pregnancies of affected sons. Muscle weakness was most pronounced in proximal and limb girdle muscles. Other frequently reported sign included (asymmetric) facial weakness (73%), reduced or absent deep tendon reflexes (45%), scoliosis (40%), and ptosis (45%). Ten participants (48%) were classified as non-manifesting. Manifesting carriers had lower functional testing scores on 6MWT and TUG compared to non-manifesting carriers. Discussion This study showed that 52% of an unselected group of XL-MTM carriers has muscle weakness (three of whom previously unclassified as manifesting). This corresponds to findings of our recent questionnaire study on self-reported symptoms in XLMTM carriers. These observations should raise awareness of the neuromuscular manifestations of the XL-MTM carrier state, and provide important epidemiological information required for future clinical trials.
- 15 November 2022
- Published by Wolters Kluwer Health in Neurology
- Vol. 99 (20) , E2223-E2233
Neuromuscular Features in XL-MTM Carriers
Background X-linked myotubular myopathy (XL-MTM) is an early onset congenital myopathy characterized by mild to severe muscle weakness in males. Objective To characterize the clinical spectrum of neuromuscular features in X-linked myotubular myopathy (XL-MTM) carriers. Methods We performed a nationwide cross-sectional study focusing on neuromuscular features in an unselected cohort of Dutch XL-MTM carriers. Participants were recruited from neuromuscular centres in the Netherlands and through the Dutch and European patient associations. Genetic results were collected. Carriers were classified based on ambulatory status and muscle weakness. We used a questionnaire focussing on medical and family history and neuromuscular symptoms. Additionally, we performed a neurological examination including Manual Muscle Testing (MMT), Timed Up and Go test (TUG), and 6 Minutes Walking Test (6MWT). Results We included 21 carriers (20 genetically confirmed and one obligate), of whom eleven (52%) carriers were classified as manifesting, with severe (non-ambulatory; n=2), moderate (minimal independent ambulation/assisted ambulation; n=2), mild (independent ambulation but with limb or axial muscle weakness; n=3) and minimal (only facial muscle weakness, n=4) phenotypes. Three of the manifesting carriers (two severe, one moderate) were from families without genetically confirmed male XL-MTM patients. Furthermore, seven manifesting carriers (one moderate; two mild; four minimal) were not classified as manifesting carriers before participation in our study. Three carriers reported a history of pneumothorax. The obstetric history revealed frequent polyhydramnios (50%) and reduced fetal movements (36%) in pregnancies of affected sons. Muscle weakness was most pronounced in proximal and limb girdle muscles. Other frequently reported sign included (asymmetric) facial weakness (73%), reduced or absent deep tendon reflexes (45%), scoliosis (40%), and ptosis (45%). Ten participants (48%) were classified as non-manifesting. Manifesting carriers had lower functional testing scores on 6MWT and TUG compared to non-manifesting carriers. Discussion This study showed that 52% of an unselected group of XL-MTM carriers has muscle weakness (three of whom previously unclassified as manifesting). This corresponds to findings of our recent questionnaire study on self-reported symptoms in XLMTM carriers. These observations should raise awareness of the neuromuscular manifestations of the XL-MTM carrier state, and provide important epidemiological information required for future clinical trials.
- Open Access
- 31 August 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (6) , 692-702
Clinical, genetic, and histological features of centronuclear myopathy in the Netherlands
Centronuclear myopathy (CNM) is a genetically heterogeneous congenital myopathy characterized by muscle weakness, atrophy, and variable degrees of cardiorespiratory involvement. The clinical severity is largely explained by genotype (DNM2, MTM1, RYR1, BIN1, TTN, and other rarer genetic backgrounds), specific mutation(s), and age of the patient. The histopathological hallmark of CNM is the presence of internal centralized nuclei on muscle biopsy. Information on the phenotypical spectrum, subtype prevalence, and phenotype–genotype correlations is limited. To characterize CNM more comprehensively, we retrospectively assessed a national cohort of 48 CNM patients (mean age = 32 ± 24 years, range 0–80, 54% males) from the Netherlands clinically, histologically, and genetically. All information was extracted from entries in the patient's medical records, between 2000 and 2020. Frequent clinical features in addition to muscle weakness and hypotonia were fatigue and exercise intolerance in more mildly affected cases. Genetic analysis showed variants in four genes (18 DNM2, 14 MTM1, 9 RYR1, and 7 BIN1), including 16 novel variants. In addition to central nuclei, histologic examination revealed a large variability of myopathic features in the different genotypes. The identification and characterization of these patients contribute to trial readiness.
- 31 August 2021
- Published by Wiley in Clinical Genetics
- Vol. 100 (6) , 692-702
Open AccessClinical, genetic, and histological features of centronuclear myopathy in the Netherlands
Centronuclear myopathy (CNM) is a genetically heterogeneous congenital myopathy characterized by muscle weakness, atrophy, and variable degrees of cardiorespiratory involvement. The clinical severity is largely explained by genotype (DNM2, MTM1, RYR1, BIN1, TTN, and other rarer genetic backgrounds), specific mutation(s), and age of the patient. The histopathological hallmark of CNM is the presence of internal centralized nuclei on muscle biopsy. Information on the phenotypical spectrum, subtype prevalence, and phenotype–genotype correlations is limited. To characterize CNM more comprehensively, we retrospectively assessed a national cohort of 48 CNM patients (mean age = 32 ± 24 years, range 0–80, 54% males) from the Netherlands clinically, histologically, and genetically. All information was extracted from entries in the patient's medical records, between 2000 and 2020. Frequent clinical features in addition to muscle weakness and hypotonia were fatigue and exercise intolerance in more mildly affected cases. Genetic analysis showed variants in four genes (18 DNM2, 14 MTM1, 9 RYR1, and 7 BIN1), including 16 novel variants. In addition to central nuclei, histologic examination revealed a large variability of myopathic features in the different genotypes. The identification and characterization of these patients contribute to trial readiness.
- Open Access
- 3 August 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (5) , e501-e512
Spectrum of Clinical Features in X-Linked Myotubular Myopathy Carriers
Objective To characterize the spectrum of clinical features in a cohort of X-linked myotubular myopathy (XL-MTM) carriers, including prevalence, genetic features, clinical symptoms, and signs, as well as associated disease burden. Methods We performed a cross-sectional online questionnaire study among XL-MTM carriers. Participants were recruited from patient associations, medical centers, and registries in the United Kingdom, Germany, and the Netherlands. We used a custom-made questionnaire, the Checklist Individual Strength (CIS), the Frenchay Activities Index (FAI), the Short Form 12 (SF-12) health survey, and the McGill Pain Questionnaire. Carriers were classified as manifesting or nonmanifesting on the basis of self-reported ambulation and muscle weakness. Results The prevalence of manifesting carriers in this study population (n = 76) was 51%, subdivided into mild (independent ambulation, 39%), moderate (assisted ambulation, 9%), and severe (wheelchair dependent, 3%) phenotypes. In addition to muscle weakness, manifesting carriers frequently reported fatigue (70%) and exercise intolerance (49%). Manifesting carriers scored higher on the overall CIS (p = 0.001), the fatigue subscale (p < 0.001), and least severe pain subscale (p = 0.005) than nonmanifesting carriers. They scored lower on the FAI (p = 0.005) and the physical component of the SF-12 health survey (p < 0.001). Conclusions The prevalence of manifesting XL-MTM carriers may be higher than currently assumed, most having a mild phenotype and a wide variety of symptoms. Manifesting carriers are particularly affected by fatigue, limitations of daily activities, pain, and reduced quality of life. Our findings should increase awareness and provide useful information for health care providers and future clinical trials.
- 3 August 2021
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (5) , e501-e512
Open AccessSpectrum of Clinical Features in X-Linked Myotubular Myopathy Carriers
Objective To characterize the spectrum of clinical features in a cohort of X-linked myotubular myopathy (XL-MTM) carriers, including prevalence, genetic features, clinical symptoms, and signs, as well as associated disease burden. Methods We performed a cross-sectional online questionnaire study among XL-MTM carriers. Participants were recruited from patient associations, medical centers, and registries in the United Kingdom, Germany, and the Netherlands. We used a custom-made questionnaire, the Checklist Individual Strength (CIS), the Frenchay Activities Index (FAI), the Short Form 12 (SF-12) health survey, and the McGill Pain Questionnaire. Carriers were classified as manifesting or nonmanifesting on the basis of self-reported ambulation and muscle weakness. Results The prevalence of manifesting carriers in this study population (n = 76) was 51%, subdivided into mild (independent ambulation, 39%), moderate (assisted ambulation, 9%), and severe (wheelchair dependent, 3%) phenotypes. In addition to muscle weakness, manifesting carriers frequently reported fatigue (70%) and exercise intolerance (49%). Manifesting carriers scored higher on the overall CIS (p = 0.001), the fatigue subscale (p < 0.001), and least severe pain subscale (p = 0.005) than nonmanifesting carriers. They scored lower on the FAI (p = 0.005) and the physical component of the SF-12 health survey (p < 0.001). Conclusions The prevalence of manifesting XL-MTM carriers may be higher than currently assumed, most having a mild phenotype and a wide variety of symptoms. Manifesting carriers are particularly affected by fatigue, limitations of daily activities, pain, and reduced quality of life. Our findings should increase awareness and provide useful information for health care providers and future clinical trials.